Hope this is just runner up news to FDA news on HemaX approval next week.
Several interesting things in this PR.
1. Preclinical trial to be at John Wayne Cancer Institute and not the UC Davies Cancer treatment center. Don't know the reason exactly, but interesting to note that the John Wayne Cancer Institute focuses on various types of cancer and cancer alone, with some FDA approved immuno-therapy treatments already in place.
2. As others pointed out, Landers is quoted as President in this PR even though his "presidency" wasn't to begin until Nov 15th officially. The PR of his replacing Ichim only mentioned his taking on the chief scientist office on 10/31.
3. The fact that pre-clinical studies are to take place outside of RGBP and under direct management of Kesari. I see this connected to T. Ichim's health issues, but also as a positive for the company in a) being able to progress the studies more rapidly as well as b) most likely in an atmosphere of GLP. I think the more associations RGBP has with established and reputable organizations for its studies, the better chance of success and potential to attract larger pharma entities with its developments.
4. While C. Ichim is not mentioned, she has previously been mentioned as providing the abstracts and presentations surrounding NR2F6 research. But her research has been focused on leukemia (hope that's not associated with T. Ichim's health issues). So the fact that this usage of NR2F6 is mentioned as a possible new IND for a variety of cancers means that either her research lead to a more general discovery of how NR2F6 works or we will have more than one NR2F6 IND potentially in the future.
The fact that this news is good and shows good progress and relationships for the company, the total lack of trading volume is a surprise. I guess this confirms that without the anticipated HemaX FDA approval, this might not go anywhere for a long time. We need HemaX approval.
